Trump said you could learn something from this man

Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.

Michael Landsittel net worth and biography

Michael Landsittel Biography and Net Worth

CFO of Blueprint Medicines

Mike has over 15 years of experience as a senior finance professional with a strategic and operational focus. Prior to joining Blueprint Medicines, Mike served as senior director of finance at Algeta US, where he led the US organization’s finance and operations efforts, which ultimately supported the successful launch of the prostate cancer drug XOFIGO® (radium Ra 223 dichloride). Before joining Algeta, Mike was the director of financial planning at Infinity Pharmaceuticalswhere he was responsible for budgeting and forecasting, including support of Infinity Pharmaceuticals’ long-range planning and capital markets activities. Prior to Infinity Pharmaceuticals, Mike held multiple business development and strategic planning roles for nearly 10 years at Genzyme. Mike is a registered CPA in the state of Illinois. He holds a B.B.A from the University of Michigan and an M.B.A. from the Tuck School of Business at Dartmouth College.

What is Michael Landsittel's net worth?: The estimated net worth of Michael Landsittel is at least $4.48 million as of May 2nd, 2024. Mr. Landsittel owns 47,286 shares of Blueprint Medicines stock worth more than $4,483,186 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Landsittel may own. Additionally, Mr. Landsittel receives an annual salary of $785,360.00 as CFO at Blueprint Medicines. Learn More about Michael Landsittel's net worth.
How old is Michael Landsittel?: Mr. Landsittel is currently 52 years old. There are 7 older executives and no younger executives at Blueprint Medicines. The oldest executive at Blueprint Medicines is Dr. Christopher K. Murray Ph.D., Senior VP of Technical Operations and Chief Technical Operations & Quality Officer, who is 60 years old. Learn More on Michael Landsittel's age.
What is Michael Landsittel's salary?: As the CFO of Blueprint Medicines Co., Mr. Landsittel earns $785,360.00 per year. There are 2 executives that earn more than Mr. Landsittel. The highest earning executive at Blueprint Medicines is Ms. Kathryn Haviland, President, CEO & Director, who commands a salary of $1,170,000.00 per year. Learn More on Michael Landsittel's salary.
How do I contact Michael Landsittel?: The corporate mailing address for Mr. Landsittel and other Blueprint Medicines executives is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. Blueprint Medicines can also be reached via phone at (617) 374-7580 and via email at [email protected]. Learn More on Michael Landsittel's contact information.
Has Michael Landsittel been buying or selling shares of Blueprint Medicines?: Michael Landsittel has not been actively trading shares of Blueprint Medicines within the last three months. Most recently, Michael Landsittel sold 10,000 shares of the business's stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $105.00, for a transaction totalling $1,050,000.00. Following the completion of the sale, the chief financial officer now directly owns 47,286 shares of the company's stock, valued at $4,965,030. Learn More on Michael Landsittel's trading history.
Who are Blueprint Medicines' active insiders?: Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Debra Durso-Bumpus (Insider), Mark Goldberg (Director), Kate Haviland (President, CEO & Director), L. Hewes (Insider), Ariel Hurley (Insider), Michael Landsittel (CFO), Philina Lee (Insider), Nicholas Lydon (Director), Tracey Mccain (EVP), Christopher Murray (Insider), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.
Are insiders buying or selling shares of Blueprint Medicines?: In the last twelve months, insiders at the biotechnology company sold shares 28 times. They sold a total of 331,047 shares worth more than $31,397,044.73. The most recent insider tranaction occured on October, 3rd when insider Fouad Namouni sold 3,633 shares worth more than $324,499.56. Insiders at Blueprint Medicines own 4.2% of the company. Learn More about insider trades at Blueprint Medicines.
Information on this page was last updated on 10/3/2024.

Michael Landsittel Insider Trading History at Blueprint Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/2/2024	Sell	10,000	$105.00	$1,050,000.00	47,286
3/28/2024	Sell	5,000	$95.00	$475,000.00	47,286
3/15/2024	Sell	13,734	$87.78	$1,205,570.52	47,286
3/7/2024	Sell	5,003	$90.69	$453,722.07	56,020
3/6/2023	Sell	3,007	$45.68	$137,359.76	48,523

Michael Landsittel Buying and Selling Activity at Blueprint Medicines

Blueprint Medicines Company Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $94.81

$92.66

$95.02

50 Day Range

MA: $90.00

$82.47

$101.39

2 Week Range

Now: $94.81

$64.79

$121.90

Volume

566,224 shs

Average Volume

692,467 shs

Market Capitalization

$6.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

Trump said you could learn something from this man

From Wide Moat Research | Ad

Here’s everything you need to know.

Michael Landsittel Biography and Net Worth

What is Michael Landsittel's net worth?

How old is Michael Landsittel?

What is Michael Landsittel's salary?

How do I contact Michael Landsittel?

Has Michael Landsittel been buying or selling shares of Blueprint Medicines?

Who are Blueprint Medicines' active insiders?

Are insiders buying or selling shares of Blueprint Medicines?